Technology | 2019.06.08
New Data Show Use of Abbott's FreeStyle® Libre System Significantly Reduces HbA1c Levels in People Living with Type 2 Diabetes
SAN FRANCISCO, June 8, 2019 /PRNewswire/ -- Today Abbott (NYSE: ABT) announced new data showing use of its FreeStyle Libre system, the company\'s revolutionary continuous glucose monitoring (CGM) technology, significantly reduced hemoglobin A1c (HbA1c) levels for people living with Type 2...
For more information, please visit
https://www.prnewswire.com:443/news-rele[...]type-2-diabetes-300864123.html
